VES001 Treatment Initiated for Frontotemporal Dementia
Dosing of VES001 has begun for patients with genetic mutations linked to frontotemporal dementia (FTD), specifically the GRN type, which is a progressive and fatal neurodegenerative disease. This marks a significant step following Vesper Bio’s receipt of clinical trial approvals from both the Netherlands and the United Kingdom to launch its Phase Ib/IIa ‘SORT-IN-2’ trial.
Innovative Approach to FTD Treatment
VES001 represents a novel, orally-administered treatment that aims to modify the disease’s course by enhancing levels of progranulin, a crucial protein for neuronal function that is often deficient in patients with FTD(GRN). Vesper anticipates that all dosing for participants will be completed by mid-2025.
Clinical Trial Launch Announcement
In Copenhagen, Denmark, Vesper Bio has officially announced the commencement of its Phase Ib/IIa Proof of Concept (POC) study for VES001, targeting frontotemporal dementia. The SORT-IN-2 trial will focus on individuals with mutations in the GRN gene, which are directly responsible for FTD(GRN). This form of dementia is characterized by early onset and is invariably deadly.
Study Details and Expectations
SORT-IN-2 will be an open-label study conducted across two sites: one at Erasmus University Medical Centre in the Netherlands, led by Professor Harro Seelaar, and the other at the Leonard Wolfson Experimental Neurology Centre in the UK, under the guidance of Professor Jonathan Rohrer. The first participant has been enrolled, and Vesper aims to complete both enrollment and dosing by mid-2025.
Expert Insights on VES001
Mads Fuglsang Kjølby, Co-Founder and interim Chief Medical Officer of Vesper Bio, stated that the primary goal of this trial is to assess the safety and tolerability of VES001 while determining its impact on progranulin levels in both cerebrospinal fluid and blood plasma. He noted that individuals with asymptomatic GRN mutations typically exhibit half the normal levels of progranulin, emphasizing the potential of VES001 to restore these levels and mitigate the progression of FTD(GRN).
Commitment to FTD Research
Paul Little, Chief Executive Officer of Vesper Bio, highlighted the rapid advancement of VES001 into this new clinical trial phase as a significant achievement for the team. He expressed the company’s dedication to providing a much-needed oral treatment option for families affected by FTD, a condition currently without an approved therapeutic solution.
Study Locations and Clinical Trials Registration
The SORT-IN-2 study will be executed at two prominent clinical facilities, ensuring rigorous oversight and expertise. The study is registered under the identifier NCT06705192 on clinicaltrials.gov.
Understanding VES001
VES001 is designed to target sortilin, a receptor on neuronal surfaces that competes with other receptors for binding to progranulin. When sortilin binds to progranulin, it leads to its degradation, resulting in lower levels of this essential protein. VES001 aims to protect neuronal cells by stabilizing and normalizing progranulin levels, making it a potentially effective treatment for patients with this deficiency.
Vesper Bio’s Mission
Vesper Bio is at the forefront of research into sortilin receptor biology and is committed to developing innovative treatments that restore progranulin levels in patients. By addressing this deficiency, Vesper’s therapies aim to have a disease-modifying impact, preserving neuronal health and function.
Frontotemporal Dementia Overview
Frontotemporal dementia (FTD), sometimes referred to as frontotemporal lobar degeneration (FTLD), encompasses a range of brain disorders that lead to the degeneration of the frontal and temporal lobes. This condition affects various cognitive functions, including behavior, judgment, and communication, significantly impairing daily living activities. FTD is the leading cause of dementia in individuals under 60 and is frequently misidentified as Alzheimer’s Disease. The GRN mutation causes the inherited form of FTD, resulting in a notable reduction of progranulin levels, which is present in approximately 12% of all FTD cases. In major global markets, there are an estimated 17,400 individuals diagnosed with FTD(GRN) and around 140,000 carriers who are at risk of developing the condition.
